Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Provenge in asymptomatic metastatic hormone-refractory prostate cancer (D9902A)
NCT01133704Phase 3Completed
- Sponsor
- Dendreon
- Start
- May 2000
- Primary completion
- Mar 2003
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, Fc-Fusion Proteins
01
Overview
A Phase 3 trial of sipuleucel-T in prostate cancer (PCa), sponsored by Dendreon. Started May 2000; status: completed.
02
Drugs
sipuleucel-T
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01133704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01133704.